Consistently, patients with BIRC3 mutations treated with FCR have the same poor outcome as patients with TP53 disruption, which represents the strongest predictor of chemorefractoriness in CLL [28]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.